Coronary and mortality risk of novel oral antithrombotic agents: a meta-analysis of large randomised trials.

ABSTRACT: Oral direct thrombin and anti-Xa inhibitors have been shown to be efficacious in the prevention and treatment of venous thromboembolism, and prevention of embolic events in atrial fibrillation. Recent studies showed that dabigatran may be associated with increased rates of myocardial infarction (MI). Coronary risk for the other agents was unclear. The aim of the study is to determine the coronary risk among four novel antithrombotic agents. Mixed treatment comparison meta-analysis. Randomised controlled trials (RCTs) on ximelagatran, dabigatran, rivaroxaban and apixaban were obtained from PubMed search (February 2012) and major scientific meeting in 2011. The random-effects model was used to evaluate the effect of these agents on MI or acute coronary syndrome (MI/ACS), major bleeding compl

SUBMITTER: Mak KH 

PROVIDER: S-EPMC3488718 | biostudies-literature | 2012

REPOSITORIES: biostudies-literature